Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

Treatment of uncontrolled asthma with dupilumab, an anti–interleukin-4 and anti–interleukin-13 receptor monoclonal antibody, in addition to usual therapy, led to a rate of severe exacerbations that was approximately 50% lower than the rate with placebo.

Uloženo v:

Podrobná bibliografie
Vydáno v:	The New England journal of medicine Ročník 378; číslo 26; s. 2486 - 2496
Hlavní autoři:	Castro, Mario, Corren, Jonathan, Pavord, Ian D, Maspero, Jorge, Wenzel, Sally, Rabe, Klaus F, Busse, William W, Ford, Linda, Sher, Lawrence, FitzGerald, J. Mark, Katelaris, Constance, Tohda, Yuji, Zhang, Bingzhi, Staudinger, Heribert, Pirozzi, Gianluca, Amin, Nikhil, Ruddy, Marcella, Akinlade, Bolanle, Khan, Asif, Chao, Jingdong, Martincova, Renata, Graham, Neil M.H, Hamilton, Jennifer D, Swanson, Brian N, Stahl, Neil, Yancopoulos, George D, Teper, Ariel
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Massachusetts Medical Society 28.06.2018
Témata:	Adolescent Adult Age Anti-Asthmatic Agents - adverse effects Anti-Asthmatic Agents - pharmacology Anti-Asthmatic Agents - therapeutic use Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Asthma Asthma - classification Asthma - drug therapy Biomarkers Blood Bronchodilator Agents - therapeutic use Bronchodilators Child Clinical medicine Committees Cytokines Double-Blind Method Drug dosages Drug Therapy, Combination Eosinophilia Eosinophilia - chemically induced Female Forced Expiratory Volume - drug effects Humans Immunotherapy Inflammation Injections, Subcutaneous - adverse effects Intention to Treat Analysis Interleukin 13 Interleukin 4 Intervention Leukocytes (eosinophilic) Male Medicine Middle Aged Monoclonal antibodies Patient safety Pharmaceuticals Population Questionnaires Receptors, Interleukin-4 - antagonists & inhibitors Respiratory function Safety Young Adult Los Angeles California United States > US California
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Treatment of uncontrolled asthma with dupilumab, an anti–interleukin-4 and anti–interleukin-13 receptor monoclonal antibody, in addition to usual therapy, led to a rate of severe exacerbations that was approximately 50% lower than the rate with placebo.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa1804092